.svg)
About
Our mission
To accelerate novel therapies for patients with devastating diseases with no treatments.
MEET our Team
The Genies behind GEn1E
Our team has strong domain expertise in developing novel, 1st-in-class drugs as well as platforms
Ritu Lal, PhD, MS
CEO, Founder and Board Director
Ritu has a track record of 3 FDA approvals in US and in Japan.
Dr. Jeffrey Hasday
Inventor of the p38 technology
Prof. Paul Shapiro
Inventor of the p38 technology
Soujanya Bhumkar, MS
AI/ML Platform
Maya Das, MD
Clinical Development
Nate Larson, PhD
Drug Product
Andrew Sonderfan, PhD, DABT
Toxicology
Beth Stannard, MS, CCRP, CCRC
Clinical Operations
Indraneel Roy, MS
AI/ML Platform
Lassi Lehtovaara, MS
AI/ML Platform
Board of Directors
François Nader, MD
Chairman of the Board
Dr. Nader currently serves as chairman of the board of directors of GEn1E, as board director of Moderna and Ring Therapeutics and as strategic advisor to Blackstone Lifesciences.
Ritu Lal, PhD, MS
CEO, Founder and Board Director
Ritu has 20+ years of Biotech/Pharma leadership experience and has taken drugs from discovery to FDA approval 3 times. She has 60+ publications and is Adjunct Faculty at University of Maryland School of Pharmacy and University of Pacific.
Noor Kamruddin
Board Director
Partner at CLEAR Ventures and Board member of Cartesian Kinetics and GEn1E. Also, Board Observer at Tignis, AICrete, Opsera, and Acante.
Alan Levy, PhD
Board Director
Board member at Intuitive Surgical, Tasso Inc., Holoclara Inc., Bardy, Dx and GEn1E. Previously, CEO at Incline Therapeutics, CEO and President at Northstar Neuroscience; CEO and President at Heartstream; and President at Heart Technology.
Soujanya Bhumkar, MS
Co-founder, AI/ML Platform and Board Director
Soujanya is a chemical engineer with an MBA from the University of Chicago. He co-founded 4 technology startups with successful exits including a major strategic partnership with Google.
Scientific Advisors
Dr. Mridul Mehta, PhD
15-year leader solving problems using data science and algorithms, including AI/ML
Dr. Anil Jegga
Dr. Anil’s work is focused on developing and applying methods to integrate the heterogeneous omics and biomedical big data to build better predictive models of disease, drug discovery and repurposing, and drug response.
Dr. David Young
Founder and CEO of Processa Pharma
Founder of GloboMax and CSO Questcor Pharmaceuticals
Founder of GloboMax and CSO Questcor Pharmaceuticals
Dr. Kevin Grimes
Director, SPARK program, Stanford
Professor, Department of Chemical and Systems Biology
Professor, Department of Chemical and Systems Biology
Dr. Mehdi Bouhaddou
Postdoctoral Scholar, Cellular Molecular
Pharmacology School of Medicine, UCSF
Pharmacology School of Medicine, UCSF
Mike Cassidy
Mike Cassidy was recently the CEO of Apollo Fusion, Inc. and a Vice President at Google.
ARDS Specialists
Dr. Carolyn Calfee
Professor in Residence of Medicine and Anesthesia at UCSF
Dr. Michael Matthay
Critical Care, Allergy and Sleep Medicine
Expert at ARDS Clinical Studies
Expert at ARDS Clinical Studies
Dr. Danny McCauley
Queens University, Belfast
Dr. Robert Fishman
Stanford trained, Pulmonary & Critical Care Physician
Also joining our journey
Investors
Our investors include Clear Ventures, Khosla Ventures, Endurance28, Stanford-StartX, Y Combinator, Vituity (a network of 6000+ Physicians in 700 hospitals)/Inflect Health along with amazing angels like Dr. Francois Nader, Thomas Ebeling, and others.
© Copyright 2018-2024. All rights reserved.
%2C%20Color%3DOriginal.svg)
